

BD EXTENDS END-TO-END SAFETY ACROSS HEALTH CARE SYSTEMS

BD Cato™ Expands IV Compounding Capabilities to Support Safe Preparation of IV Medications

FRANKLIN LAKES, N.J., SEPT. 11, 2017 – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced a new version of its IV preparation solution, BD Cato, featuring enhancements that extend IV compounding safety to a broader set of IV medications and help enable more accurate preparation of IVs by detecting wrong drug and dose errors in real time.

The latest release delivers enhanced safety and workflow efficiencies in medication preparation via gravimetric and barcoding technology, with expanded capabilities to detect potential medication errors for a broader set of sterile preparations. This release is designed to increase the accuracy of IV medications during the compounding process, making safe IV compounding possible in more hospitals across the U.S.

Enhancements include:

- **Volumetric workflow option:** While BD always recommends gravimetric verification as the highest standard of safety, the addition of the volumetric option enables a guided step-by-step IV compounding workflow for circumstances where gravimetric compounding may not make sense.
- **Interoperability with Epic™ EMR** for inbound orders and outbound NDC usage information, enabling more accurate billing.
- **Gravimetric batching capabilities** for a safer yet streamlined and efficient workflow that enables anticipatory and patient-specific batching operations.
- **Expanded Implementation Database** that includes critical drug information to make it faster and easier for pharmacies to get up and running with the IV compounding solution.

"BD Cato software prevented a medication error during IV compounding that could have easily slipped through the cracks," said Nathan Barnes, PharmD, Lead Pharmacist, UNC Healthcare. "Had BD Cato software not been in place, it would have been extremely easy to miss an odd medication concentration that was not appropriate for the patient's needs, which would have yielded a dose two times above the ordered dose."

In an upcoming webcast, industry expert Dr. Lindsey Amerine of UNC Medical Center, will share her experiences implementing BD Cato in both oncology and general pharmacies and the impact it has had on her organization. [Register for the September 13th webcast.](#)

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.